Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Prostate Cancer | Primary research

miR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1

Authors: Dapeng Zhang, Xiaodong Liu, Qingwei Zhang, Xin Chen

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

This study aimed to uncover the effect of miR-138-5p on the proliferation and metastasis of PCa cell lines, and further explore the potential regulatory mechanisms via regulating FOXC1.

Methods

60 pairs cancer tissues and corresponding paracancerous ones from PCa patients were collected to assess the expression level of miR-138-5p by qRT-PCR. Subsequently, over-expression of miR-138-5p were established to explore the proliferation and metastasis of miR-138-5p in PCa cell lines was analyzed by CCK-8, Transwell assay and Wounding healing assay, respectively. Bioinformatics analysis and luciferase reporter gene assay were performed to search for the target genes of miR-138-5p, and FOXC1 was selected. Finally, the biological role of miR-138-5p and FOXC1 in the progression of PCa was clarified by a series of rescue experiments.

Results

The results of qRT-PCR revealed that miR-138-5p was lowly expressed in PCa tissues and cell lines. Besides, the PCa patients with low-miR-138-5p had a high Gleason score, lymph node metastasis and poor prognosis of PCa, compared with these patients with high-miR-138-5p. Over-expression of miR-138-5p inhibited the proliferative, migratory and invasive capacities of PC-3 and DU-145 cells. Bioinformatics analysis and luciferase reporter gene assay suggested that FOXC1 was predicted to be the target gene of miR-138-5p. Moreover, FOXC1 expression level was negatively correlated to that of miR-138-5p in PCa tissues. Importantly, over-expression of FOXC1 could reverse miR-138-5p mimic induced-inhibition of PCa malignant progression.

Conclusions

Downregulated miR-138-5p was closely associated with high Gleason score, more lymph node metastasis and poor prognosis of PCa patients. In addition, miR-138-5p alleviated the malignant progression of PCa by targeting and downregulating FOXC1.
Literature
1.
go back to reference Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14.CrossRef Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14.CrossRef
2.
go back to reference Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198:1230–40.CrossRef Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198:1230–40.CrossRef
3.
go back to reference Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al OA, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11:18–31.CrossRef Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al OA, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11:18–31.CrossRef
4.
go back to reference Fenner A. Prostate cancer: ERSPC calculator recalibrated for China. Nat Rev Urol. 2017;14:66.CrossRef Fenner A. Prostate cancer: ERSPC calculator recalibrated for China. Nat Rev Urol. 2017;14:66.CrossRef
5.
go back to reference Reulen RC, de Vogel S, Zhong W, Zhong Z, Xie LP, Hu Z, et al. Physical activity and risk of prostate and bladder cancer in China: the South and East China case-control study on prostate and bladder cancer. PLoS ONE. 2017;12:e178613.CrossRef Reulen RC, de Vogel S, Zhong W, Zhong Z, Xie LP, Hu Z, et al. Physical activity and risk of prostate and bladder cancer in China: the South and East China case-control study on prostate and bladder cancer. PLoS ONE. 2017;12:e178613.CrossRef
6.
go back to reference Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014;44:433–40.CrossRef Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014;44:433–40.CrossRef
7.
go back to reference Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med. 2019;58:326–39.CrossRef Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med. 2019;58:326–39.CrossRef
8.
go back to reference Shore N. Management of early-stage prostate cancer. Am J Manage Care. 2014;20:S260–72. Shore N. Management of early-stage prostate cancer. Am J Manage Care. 2014;20:S260–72.
9.
go back to reference Qu M, Ren SC, Sun YH. Current early diagnostic biomarkers of prostate cancer. Asian J Androl. 2014;16:549–54.CrossRef Qu M, Ren SC, Sun YH. Current early diagnostic biomarkers of prostate cancer. Asian J Androl. 2014;16:549–54.CrossRef
10.
go back to reference Bryant RJ, Lilja H. Emerging PSA-based tests to improve screening. Urol Clin N Am. 2014;41:267–76.CrossRef Bryant RJ, Lilja H. Emerging PSA-based tests to improve screening. Urol Clin N Am. 2014;41:267–76.CrossRef
11.
go back to reference Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, et al. Expression of cancer-associated genes in prostate tumors. Exp Oncol. 2017;39:131–7.CrossRef Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, et al. Expression of cancer-associated genes in prostate tumors. Exp Oncol. 2017;39:131–7.CrossRef
12.
go back to reference Flores IE, Sierra-Fonseca JA, Davalos O, Saenz LA, Castellanos MM, Zavala JK, et al. Stress alters the expression of cancer-related genes in the prostate. BMC Cancer. 2017;17:621.CrossRef Flores IE, Sierra-Fonseca JA, Davalos O, Saenz LA, Castellanos MM, Zavala JK, et al. Stress alters the expression of cancer-related genes in the prostate. BMC Cancer. 2017;17:621.CrossRef
13.
go back to reference Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55:715–36.CrossRef Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55:715–36.CrossRef
14.
go back to reference Luu HN, Lin HY, Sorensen KD, Ogunwobi OO, Kumar N, Chornokur G, et al. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017;17:18.CrossRef Luu HN, Lin HY, Sorensen KD, Ogunwobi OO, Kumar N, Chornokur G, et al. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017;17:18.CrossRef
15.
go back to reference Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15:1–19.CrossRef Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15:1–19.CrossRef
16.
go back to reference Tafrihi M, Hasheminasab E. MiRNAs: biology, biogenesis, their web-based tools, and databases. Microrna. 2019;8:4–27.CrossRef Tafrihi M, Hasheminasab E. MiRNAs: biology, biogenesis, their web-based tools, and databases. Microrna. 2019;8:4–27.CrossRef
17.
go back to reference Rivera-Barahona A, Perez B, Richard E, Desviat LR. Role of miRNAs in human disease and inborn errors of metabolism. J Inherit Metab Dis. 2017;40:471–80.CrossRef Rivera-Barahona A, Perez B, Richard E, Desviat LR. Role of miRNAs in human disease and inborn errors of metabolism. J Inherit Metab Dis. 2017;40:471–80.CrossRef
18.
go back to reference Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.CrossRef Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.CrossRef
19.
go back to reference Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15:429.CrossRef Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15:429.CrossRef
20.
go back to reference Li M, Huo X, Davuljigari CB, Dai Q, Xu X. MicroRNAs and their role in environmental chemical carcinogenesis. Environ Geochem Health. 2019;41:225–47.CrossRef Li M, Huo X, Davuljigari CB, Dai Q, Xu X. MicroRNAs and their role in environmental chemical carcinogenesis. Environ Geochem Health. 2019;41:225–47.CrossRef
21.
go back to reference Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts. 2017;8:61–81.CrossRef Armand-Labit V, Pradines A. Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts. 2017;8:61–81.CrossRef
22.
go back to reference Kalinina EV, Ivanova-Radkevich VI, Chernov NN. Role of microRNAs in the regulation of redox-dependent processes. Biochemistry (Mosc). 2019;84:1233–46.CrossRef Kalinina EV, Ivanova-Radkevich VI, Chernov NN. Role of microRNAs in the regulation of redox-dependent processes. Biochemistry (Mosc). 2019;84:1233–46.CrossRef
23.
go back to reference Yang Z, Jiang S, Cheng Y, Li T, Hu W, Ma Z, et al. FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles. Ther Adv Med Oncol. 2017;9:797–816.CrossRef Yang Z, Jiang S, Cheng Y, Li T, Hu W, Ma Z, et al. FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles. Ther Adv Med Oncol. 2017;9:797–816.CrossRef
24.
go back to reference Han B, Bhowmick N, Qu Y, Chung S, Giuliano AE, Cui X. FOXC1: an emerging marker and therapeutic target for cancer. Oncogene. 2017;36:3957–63.CrossRef Han B, Bhowmick N, Qu Y, Chung S, Giuliano AE, Cui X. FOXC1: an emerging marker and therapeutic target for cancer. Oncogene. 2017;36:3957–63.CrossRef
25.
go back to reference Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016;7:45370–84.CrossRef Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016;7:45370–84.CrossRef
26.
go back to reference Tian S, Guo X, Yu C, Sun C, Jiang J. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. Oncotarget. 2017;8:11071–82.CrossRef Tian S, Guo X, Yu C, Sun C, Jiang J. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. Oncotarget. 2017;8:11071–82.CrossRef
27.
go back to reference Ni WJ, Leng XM. miRNA-dependent activation of mRNA translation. Microrna. 2016;5:83–6.CrossRef Ni WJ, Leng XM. miRNA-dependent activation of mRNA translation. Microrna. 2016;5:83–6.CrossRef
28.
go back to reference Stavast CJ, Erkeland SJ. The non-canonical aspects of microRNAs: many roads to gene regulation. Cells-Basel. 2019;19:1465.CrossRef Stavast CJ, Erkeland SJ. The non-canonical aspects of microRNAs: many roads to gene regulation. Cells-Basel. 2019;19:1465.CrossRef
29.
go back to reference Mork S, Pletscher-Frankild S, Palleja CA, Gorodkin J, Jensen LJ. Protein-driven inference of miRNA-disease associations. Bioinformatics. 2014;30:392–7.CrossRef Mork S, Pletscher-Frankild S, Palleja CA, Gorodkin J, Jensen LJ. Protein-driven inference of miRNA-disease associations. Bioinformatics. 2014;30:392–7.CrossRef
Metadata
Title
miR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1
Authors
Dapeng Zhang
Xiaodong Liu
Qingwei Zhang
Xin Chen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01386-6

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine